| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Myasthenia Gravis Panel 3
Test Code10211
CPT Codes
86041, 86042, 86043, 86255
Includes
Acetylcholine Receptor Binding Antibody
Acetylcholine Receptor Blocking Antibody
Acetylcholine Receptor Modulating Antibody
Striated Muscle Antibody with Reflex to Titer
If Striated Muscle Antibody Screen is positive, then Striated Muscle Antibody Titer will be performed at an additional charge (CPT code(s): 86256).
Acetylcholine Receptor Blocking Antibody
Acetylcholine Receptor Modulating Antibody
Striated Muscle Antibody with Reflex to Titer
If Striated Muscle Antibody Screen is positive, then Striated Muscle Antibody Titer will be performed at an additional charge (CPT code(s): 86256).
Preferred Specimen
2 mL serum collected in an SST® (red-top) tube
Minimum Volume
0.8 mL
Transport Temperature
Room temperature
Specimen Stability
Room temperature: 4 days
Refrigerated: 14 days
Frozen: 30 days
Refrigerated: 14 days
Frozen: 30 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
See individual tests
Methodology
See individual tests
FDA Status
Acetylcholine Receptor Modulating Antibody: This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Set up: Mon, Thu; Report available: 2-6 days
Clinical Significance
Myasthenia Gravis is a neurological disorder characterized by a decrease in acetylcholine receptors. Patients exhibit skeletal muscle weakness and fatigability. Approximately 80% of patients with Myasthenia Gravis, excluding ocular involvement only, have detectable acetylcholine receptor antibody. There is a strong correlation between the presence of striated muscle antibody and the presence of thymoma.
